There are some good headline numbers in that report, but there...

There are some good headline numbers in that report, but there are also some good numbers & other info hidden in parts of the report that you need to do a bit more digging for.

- Infusions was profitable to the tune of $1.2M, or a 7.8% Margin

- We are currently sitting on $4.45M of Inventory (which is presumably a lot of high margin consumables for nRAH and high margin Adapt) - if we assume that on average inventory has 50% G.P, it grosses up to $8.9M of future revenue where the COS has already been paid for in prior periods. (good for cash conversion in upcoming periods).

- *Trade Receivables were $3255K (good headstart for cash collections this Q), but trade payables were only $1962K

*Excludes ~$1M related to a Townsville Hospital contract that is converted to cash sporadically.

- Rodne & the Other Ex-Directors have completely sold out (no more relentless selling from people with an axe to grind)

- The CFO of the company (ex Cochlear) took 20% of his ex-super wage as share based payments.

- 'it is appropriate to adopt the going concern basis in the preparation of the financial report after consideration of the following factors: New markets for the Groups ADAPT® products including India, Australia, Philippines, Taiwan, Vietnam, Spain, Hungary, Baltics and Mexico'

Looking forward to some more info from the webinar on Tues!